Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer

被引：1
|
作者：
Koshkin, V. S. [1 ]
Sun, Y. [2 ]
Osterman, C. K. [3 ]
Natesan, D. [4 ]
Su, C. [5 ]
Lemke, E. [6 ]
Khaki, A. R. [7 ]
Johnson, A. [8 ]
Owens, X. [9 ]
Park, J. J. [5 ]
Basu, A. [9 ]
Barata, P. M. Coelho [8 ]
Davis, N. [10 ]
Grivas, P. [11 ]
Milowsky, M. [3 ]
Kilari, D. [6 ]
Alva, A. [5 ]
机构：
[1] UCSF, Helen Diller Family Comprehens Canc Ctr, Dept Med, Div Med Oncol, San Francisco, CA USA
[2] Univ Michigan, Biostat, Ann Arbor, MI USA
[3] Univ N Carolina, Med, Chapel Hill, NC 27515 USA
[4] UCSF, Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol, San Francisco, CA USA
[5] Univ Michigan, Med, Ann Arbor, MI 48109 USA
[6] Med Coll Wisconsin, Med, Milwaukee, WI 53226 USA
[7] Univ Washington, Med, Seattle, WA 98195 USA
[8] Tulane Univ, Dept Med Oncol, New Orleans, LA 70118 USA
[9] Univ Alabama Birmingham, Med, Birmingham, AL USA
[10] Vanderbilt Univ, Med Ctr, Med, Nashville, TN USA
[11] Univ Washington, Seattle Canc Care Alliance, Hematol Oncol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.843
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
771P
引用
收藏
页码：S594 / S594
页数：1
相关论文
共 50 条
  • [1] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Powles, T.
    Valderrama, B. P.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano, D.
    Fornarini, G.
    Li, J. R.
    Guemues, M.
    Mar, N.
    Loriot, Y.
    Flechon, A.
    Duran, I
    Drakaki, A.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10): : 875 - 888
  • [2] Enfortumab Vedotin in Advanced Urothelial Carcinoma
    Petrylak, Daniel P.
    Powles, Thomas
    Rosenberg, Jonathan E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01): : 93 - 94
  • [3] Enfortumab Vedotin in urothelial cancer
    Alt, Marie
    Stecca, Carlos
    Tobin, Swanee
    Jiang, Di Maria
    Sridhar, Srikala S.
    THERAPEUTIC ADVANCES IN UROLOGY, 2020, 12
  • [4] Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Catalano, Martina
    Santoni, Matteo
    Roviello, Giandomenico
    EUROPEAN UROLOGY, 2024, 86 (03) : 283 - 283
  • [5] Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer
    Petrylak, Daniel P.
    Chia, Yen Lin
    Yu, Evan Y.
    Powles, Thomas
    Flaig, Thomas W.
    Loriot, Yohann
    O'Donnell, Peter H.
    Heath, Elisabeth I.
    Kojima, Takahiro
    Park, Se Hoon
    Sonpavde, Guru P.
    Picus, Joel
    Matsubara, Nobuaki
    Obara, Wataru
    Chudasama, Vaishali
    Poondru, Srinivasu
    Harrison, Michael
    Kim, Eric
    Brancato, Sam Joseph
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Milowsky, Matthew, I
    Friedlander, Terence W.
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Srinivas, Sandy
    Merchan, Jaime R.
    McKay, Rana R.
    Petrylak, Daniel P.
    Sasse, Carolyn
    Moreno, Blanca Homet
    Yu, Yao
    Carret, Anne-Sophie
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 22 - +
  • [7] Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
    Koshkin, Vadim S.
    Henderson, Nicholas
    James, Marihella
    Natesan, Divya
    Freeman, Dory
    Nizam, Amanda
    Su, Christopher T.
    Khaki, Ali Raza
    Osterman, Chelsea K.
    Glover, Michael J.
    Chiang, Ryan
    Makrakis, Dimitrios
    Talukder, Rafee
    Lemke, Emily
    Olsen, T. Anders
    Jain, Jayanshu
    Jang, Albert
    Ali, Alicia
    Jindal, Tanya
    Chou, Jonathan
    Friedlander, Terence W.
    Hoimes, Christopher
    Basu, Arnab
    Zakharia, Yousef
    Barata, Pedro C.
    Bilen, Mehmet A.
    Emamekhoo, Hamid
    Davis, Nancy B.
    Shah, Sumit A.
    Milowsky, Matthew I.
    Gupta, Shilpa
    Campbell, Matthew T.
    Grivas, Petros
    Sonpavde, Guru P.
    Kilari, Deepak
    Alva, Ajjai S.
    CANCER, 2022, 128 (06) : 1194 - 1205
  • [8] Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
    Fukuokaya, Wataru
    Koike, Yuhei
    Yata, Yuji
    Komura, Kazumasa
    Uchimoto, Taizo
    Tsujino, Takuya
    Saruta, Masanobu
    Takahara, Kiyoshi
    Fujita, Kazutoshi
    Minami, Takafumi
    Adachi, Takahiro
    Hirasawa, Yosuke
    Hashimoto, Takeshi
    Ohno, Yoshio
    Uemura, Hirotsugu
    Shiroki, Ryoichi
    Azuma, Haruhito
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (04) : 342 - 347
  • [9] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Powles, Thomas
    Rosenberg, Jonathan E.
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Wu, Chunzhang
    Campbell, Mary
    Matsangou, Maria
    Petrylak, Daniel P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1125 - 1135
  • [10] Pembrolizumab plus enfortumab vedotin in urothelial cancer
    Santoni, Matteo
    Takeshita, Hideki
    Massari, Francesco
    Bamias, Aristotelis
    Cerbone, Linda
    Fiala, Ondrej
    Mollica, Veronica
    Buti, Sebastiano
    Santoni, Angela
    Bellmunt, Joaquim
    NATURE REVIEWS UROLOGY, 2024, 21 (07) : 387 - 388
12345